Prescient Therapeutics’ PTX-100 trial expands to top US cancer centre
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the company’s latest milestone —...
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the company’s latest milestone —...
The first United States clinical trial site for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF)’s Phase 2a study...
Prescient Therapeutics CEO James McDonnell talked with Proactive about promising developments surrounding the company’s lead...
For those affected by Cutaneous T-Cell Lymphoma (CTCL), a rare and aggressive cancer, treatment options...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is targeting A$7 million through a Share Purchase Plan (SPP) to...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is aiming to establish new frontiers in cancer care, with...
Prescient Therapeutics (ASX: PTX) earlier this week began its Phase 2A clinical trial of PTX-100...
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the initiation of a Phase...
Prescient Therapeutics Ltd has kicked off its Phase 2a clinical trial evaluating PTX-100 for relapsed...
Prescient Therapeutics Ltd has received Fast Track Designation from the United States Food and Drug...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.